Fibrinogen-Like Protein 1 as a Novel Biomarker of Psoriasis Severity

References

• Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006
   PubMed Web of Science ®Google Scholar
• Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(suppl_2):ii18–ii23. doi:10.1136/ard.2004.033217
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Romanelli P, Volpe E, et al. Scanning the immunopathogenesis of psoriasis. Int J Mol Sci. 2018;19(1):179. doi:10.3390/ijms19010179
   PubMed Web of Science ®Google Scholar
• Morizane S, Yamasaki K, Mühleisen B, et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Investig Dermatol. 2012;132(1):135–143. doi:10.1038/jid.2011.259
   PubMed Web of Science ®Google Scholar
• Surcel M, Huica R, Constantin C, et al. Biomarkers insights in psoriasis-regulatory cytokines. Curr Biomark. 2018;7(1):3–11. doi:10.2174/2468422807666180320125713
   Google Scholar
• Fotiadou C, Lazaridou E, Sotiriou E, et al. Targeting IL-23 in psoriasis: current perspectives. Psoriasis. 2018;8:1–5. doi:10.2147/PTT.S98893
   PubMed Web of Science ®Google Scholar
• Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. doi:10.3390/ijms20061475
   PubMed Web of Science ®Google Scholar
• Xiuping C, Keli X, Lidian C, et al. TNF-alpha, a potent lipid metabolism regulator. Cell Biochem Funct. 2009;27(7):407–416. doi:10.1002/cbf.1596
   PubMed Web of Science ®Google Scholar
• Stachowiak M, Flisikowski K. Analysis of allele-specific expression of seven candidate genes involved in lipid metabolism in pig skeletal muscle and fat tissues reveals allelic imbalance of ACACA, LEP, SCD, and TNF. J Appl Genet. 2019;60(1):97–101. doi:10.1007/s13353-019-00485-z
   PubMed Web of Science ®Google Scholar
• Hua Q, Reina D, Kavita I-W, et al. Origin and function of stress-induced IL-6 in murine models. Cell. 2020;182(6):1660. doi:10.1016/j.cell.2020.08.044
   PubMed Web of Science ®Google Scholar
• Patin F, Baranek T, Vourc’h P, et al. Combined metabolomics and transcriptomics approaches to assess the IL-6 blockade as a therapeutic of ALS: deleterious alteration of lipid metabolism. Neurotherapeutics. 2016;13(4):905–917. doi:10.1007/s13311-016-0461-3
   PubMed Web of Science ®Google Scholar
• Owczarczyk-Saczonek A, Czerwi´nska J, Placek W. The role of regulatory T cells and anti-inflammatory cytokines in psoriasis. Acta Dermatovenerol Alp Panonica Adriat. 2018;27:17–23.
   PubMed Web of Science ®Google Scholar
• Saxena A, Khosraviani S, Noel S, et al. Interleukin-10 paradox: a potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine. 2015;74(1):27–34. doi:10.1016/j.cyto.2014.10.031
   PubMed Web of Science ®Google Scholar
• Trifunovi CJ, Miller L, Debeljak Ž, et al. Pathologic patterns of interleukin 10 expression: a review. Biochem Med. 2015;25:36–48. doi:10.11613/BM.2015.004
   Web of Science ®Google Scholar
• Wu HT, Ou HY, Hung HC, et al. A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes. Diabetologia. 2016;59(8):1732–1742. doi:10.1007/s00125-016-3991-7
   PubMed Web of Science ®Google Scholar
• Sheng Y, Jin X, Xu J, et al. Sequencing-based approach identified three new susceptibility loci for psoriasis. Nat Commun. 2014;5(1):4331. doi:10.1038/ncomms5331
   PubMed Web of Science ®Google Scholar
• Gulati N, Suárez-Fariñas M, Correa da Rosa J, et al. Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions. F1000research. 2015;4:149. doi:10.12688/f1000research.6581.1
   PubMedGoogle Scholar
• Ellis J, Marks Daniel JB, Srinivasan N, et al. Depletion of LAG3 T cells translated to pharmacology and improvement in psoriasis disease activity: a phase I randomized study of mAb GSK2831781. Clin Pharmacol Ther. 2020;109(5):1293–1303. doi:10.1002/cpt.2091
   PubMed Web of Science ®Google Scholar
• Wang J, Sanmamed MF, Datar I, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG3. Cell. 2019;176(1–2):334–347. doi:10.1016/j.cell.2018.11.010
   PubMed Web of Science ®Google Scholar
• Liu S, Guo Y, Lu L, et al. Fibrinogen-like protein 1 is a novel biomarker for predicting disease activity and prognosis of rheumatoid arthritis. Front Immunol. 2020;11:579228. doi:10.3389/fimmu.2020.579228
   PubMed Web of Science ®Google Scholar
• Sun X-L, Qiao L-C, Gong J, et al. Proteomics identifies a novel role of fibrinogen-like protein 1 in Crohn’s disease. World J Gastroenterol. 2021;27(35):5946–5957. doi:10.3748/wjg.v27.i35.5946
   PubMed Web of Science ®Google Scholar
• Feldman SR, Goffe B, Rice G, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9(9):504–513.
   PubMed Web of Science ®Google Scholar
• Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24:10–16. doi:10.1111/j.1468-3083.2009.03562.x
   PubMed Web of Science ®Google Scholar
• Psoriasis Professional Committee of Dermatology and venereology Branch of Chinese Medical Association. Guidelines for the diagnosis and treatment of psoriasis in China (2018 simplified version). Chin J Dermatol. 2019;52(4):223–230.
   Google Scholar
• Yanyan F, Junling L, Xiongming P. Prevalence of psoriasis with metabolic syndrome in Xinjiang. Chin J Leprosy Skin Dis. 2016;32(03):153–155.
   Google Scholar
• Metabolic Syndrome Research Collaborative Group of Diabetes Branch of Chinese Medical Association. Suggestions of diabetes branch of Chinese medical association on metabolic syndrome. Chin J Diabetes. 2004;12(5):156–161.
   Google Scholar
• Robertson J, Porter D, Sattar N, et al. Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Ann Rheum Dis. 2017;76(11):1949–1952. doi:10.1136/annrheumdis-2017-211708
   PubMed Web of Science ®Google Scholar
• Chan KY, Lai PB, Squire JA, et al. Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma. Mod Pathol. 2006;19(12):1546–1554. doi:10.1038/modpathol.3800674
   PubMed Web of Science ®Google Scholar
• Nayeb-Hashemi H, Desai A, Demchev V, et al. Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development. Biochem Biophys Res Commun. 2015;465(2):167–173. doi:10.1016/j.bbrc.2015.07.078
   PubMed Web of Science ®Google Scholar
• Demchev V, Malana G, Vangala D, et al. Targeted deletion of fibrinogen like protein 1 reveals a novel role in energy substrate utilization. PLoS One. 2013;8(3):e58084. doi:10.1371/journal.pone.0058084
   PubMed Web of Science ®Google Scholar
• Jung TW, Chung YH, Kim HC, et al. Hyperlipidemia- induced hepassocin in the liver contributes to insulin resistance in skeletal muscle. Mol Cell Endocrinol. 2018;470:26–33. doi:10.1016/j.mce.2017.10.014
   PubMed Web of Science ®Google Scholar
• Ou HY, Wu HT, Lin CH, et al. The hepatic protection effects of hepassocin in hyperglycemic crisis. J Clin Endocrinol Metab. 2017;102(7):2407–2415. doi:10.1210/jc.2016-3287
   PubMed Web of Science ®Google Scholar
• Yu HT, Yu M, Li CY, et al. Specific expression and regulation of hepassocin in the liver and down-regulation of the correlation of hnf1alpha with decreased levels of hepassocin in human hepatocellular carcinoma. J Biol Chem. 2009;284(20):13335–13347. doi:10.1074/jbc.M806393200
   PubMed Web of Science ®Google Scholar
• Wu HT, Chen SC, Fan KC, et al. Targeting fibrinogen-like protein 1 is a novel therapeutic strategy to combat obesity. FASEB J. 2020;34(2):2958–2967. doi:10.1096/fj.201901925R
   PubMed Web of Science ®Google Scholar
• Ani M, Honghuang L, Chansuk K, et al. Lymphocyte activation gene-3-associated protein networks are associated with HDL-cholesterol and mortality in the trans-omics for precision medicine program. Commun Biol. 2022;5(1):362. doi:10.1038/s42003-022-03304-0
   PubMed Web of Science ®Google Scholar
• Rodriguez A. High HDL-cholesterol paradox: SCARB1-LAG3-HDL axis. Curr Atheroscler Rep. 2021;23(1):5. doi:10.1007/s11883-020-00902-3
   PubMed Web of Science ®Google Scholar